Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: December 03, 2024)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02620852

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer Scientific Title

Purpose

To learn if risk-based breast screening is as safe and effective as annual mammogram screening for reducing risk and detecting breast cancer.

Who is this for?

Women between the ages of 40 and 70 who have never been diagnosed with breast cancer or ductal carcinoma in situ (DCIS). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups, or you can choose your study group. Group 1: Personalized, Risk-Based Screening <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendations based on comprehensive, personal risk assessment</li> <li class="seamTextUnorderedListItem">Saliva sample genetic test</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li> </ul> Group 2: Standard Annual Screening <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendation for annual mammograms</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.</li> <li class="seamTextUnorderedListItem">This study will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer as annual screening. </li> <li class="seamTextUnorderedListItem">This study is available in English and Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02620852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thewisdomstudy.org/' target='_blank'>WISDOM: Study Information Page</a> </li></ul>

NEAREST SITE: 3 miles
UCSF Breast Care Center
San Francisco,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03053193

The FLEX Registry: MammaPrint Testing With or Without BluePrint Testing For People With Stage I-III Breast Cancer

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Scientific Title

Purpose

To create a large registry of tumor samples to help researchers find new cancer biomarkers and design future clinical trials.

Who is this for?

People with stage I, stage II, or stage III breast cancer who received MammaPrint testing, with or without BluePrint genomic testing, of their tumor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

For this data collection registry, you will: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide a sample of your tumor (taken during a routine procedure)</li> <li class="seamTextUnorderedListItem">Allow information about your breast cancer treatment to be included in the registry</li> <li class="seamTextUnorderedListItem">Information will be collected from you when you enroll in the registry, during treatment, 1 year after treatment ends; and 2, 5, and 10 years after your diagnosis</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The FLEX Registry will create a database of clinical and genomic information collected from patients who have had their tumor tested with MammaPrint, with or without BluePrint genomic testing. </li> <li class="seamTextUnorderedListItem">MammaPrint is a diagnostic test done on a tumor sample to help guide treatment decisions. The results tell you and your doctor if you have a low or high risk of recurrence. </li> <li class="seamTextUnorderedListItem">BluePrint is a molecular test done on the tumor sample to further classify your risk of recurrence.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03053193' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/clinical-trials/ongoing-studies/' target='_blank'>Trial Sponsor Information Page: FLEX Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/mammaprint' target='_blank'>Breastcancer.org: MammaPrint Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/our-tests/mammaprint/' target='_blank'>Agendia Information Page: MammaPrint Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/diagnostic-products/blueprint.html#' target='_blank'>Agendia Information Page: BluePrint Test</a> </li></ul>

NEAREST SITE: 5 miles
University of California, San Francisco
San Francisco,CA

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05964504

PLUMB Registry for Metastatic Lobular Breast Cancer

Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer Scientific Title

Purpose

To create a registry to study metastatic lobular breast cancer, treatment patterns, and overall survival.

Who is this for?

People with stage IV (metastatic) lobular breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples will be used to study the relationship between ctDNA and disease progression.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">This trial will also develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05964504' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.ucsf.edu/trial/NCT05964504' target='_blank'>University of California, San Francisco: Trial Information Page</a> </li></ul>

NEAREST SITE: 8 miles
Bay Area Breast Surgeons Inc
Emeryville,CA

VISITS: 2 visits in 1 year

PHASE: NA

NCT ID: NCT05334069

Collecting Blood Samples From People With and Without Breast Cancer to Evaluate Tests for Early Cancer Detection

Blinded Reference Set for Multicancer Early Detection Blood Tests Scientific Title

Purpose

To collect blood and tissue samples from people with breast cancer and people without breast cancer to evaluate tests for early cancer detection.

Who is this for?

People 40-75 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment, or who do not have breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood samples, 2 times</li> <li class="seamTextUnorderedListItem">Provide tissue samples (for people with cancer), 2 times</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collecting and storing samples of blood and tissue from patients with and without breast cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05334069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis' target='_blank'>National Cancer Institute: How Cancer Is Diagnosed</a> </li></ul>

NEAREST SITE: 158 miles
Central California ENT Medical Group
Fresno,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05435066

Collecting Blood and Tissue Samples to Create an Early Cancer Detection Test

Cancer ORigin Epigenetics-Harbinger Health - Collection of Blood and Tissue Samples From Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (CORE-HH) Scientific Title

Purpose

To develop a test for early cancer detection.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who were diagnosed in the last 6 months and have not yet begun treatment, people with stage 0 (DCIS) breast cancer, and people who have not had cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and tissue samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer and people without cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05435066' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 171 miles
Carson Tahoe Regional Medical Center
Carson City,NV

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT04314401

NCI Cancer Moonshot Biobank for Stage III-IV Breast Cancer

Cancer Moonshot Biobank Research Protocol Scientific Title

Purpose

To collect tissue samples, blood samples, and medical information from people with breast cancer to study how cancer changes over time and during treatment.

Who is this for?

People with stage III or stage IV (metastatic) breast cancer who are receiving or planning to receive treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue and blood samples before, during, and after treatment</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collecting tissue samples, blood samples, and medical information over time may help researchers better understand resistance to treatment, changes in genes, and other factors about how cancer responds to treatment.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04314401' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://moonshotbiobank.cancer.gov/' target='_blank'>National Cancer Institute: Cancer Moonshot Biobank</a> </li></ul>

NEAREST SITE: 336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05978128

Increasing Breast Cancer Screening Using Advocates and Supporters

Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates Scientific Title

Purpose

To investigate why some people may receive breast cancer screening but not lung cancer screening and to determine if advocates and supporters can increase screening.

Who is this for?

People at least 40 years old who do not currently have cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online educational materials, 3 times within 2 years</li> <li class="seamTextUnorderedListItem">Meet with a patient navigator</li> <li class="seamTextUnorderedListItem">Education materials to share with friends/family on benefits of breast cancer screening</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer screening with mammography is widely accepted and commonly used.</li> <li class="seamTextUnorderedListItem">Advocates and supporters of lung cancer screening may increase the willingness to receive this screening.</li> <li class="seamTextUnorderedListItem">This trial also includes lung cancer screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05978128' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05786664

Registry to Study Breast Cancer and Treatment Outcomes for Women with Stage I-III Breast Cancer

A Comprehensive Breast Cancer Survivorship Biorepository Scientific Title

Purpose

To create a registry of biological samples to study breast cancer and treatment outcomes.

Who is this for?

Women with stage I, stage II, or stage III breast cancer that was diagnosed within the last 7 years and who have completed treatment. Your cancer must not have come back (recurrence). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Creation of this collection of biological samples (registry) will allow research into the links between biological features of these samples and cancer outcomes.</li> <li class="seamTextUnorderedListItem">The study will also study the relationship between social determinants of health, environmental exposure, and lifestyle.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish, Chinese, and Korean.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05786664' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 375 miles
Knowledge Research Center
Orange,CA

VISITS: 2 times within 6 months, then 3 times within 2 years

PHASE: NA

NCT ID: NCT04638751

Stool and Blood Sample Bank to Develop New Treatments for Triple Negative Breast Cancer

ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment Scientific Title

Purpose

To collect stool and blood samples to study gut microbiomes, study cancer biomarkers, and develop new treatments.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer planning to receive their next treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool and blood samples, 2 times within 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool samples will be used to study your gut microbiome, which are the microorganisms that live in your digestive system. Drugs that target your microbiome may be helpful to treat cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04638751' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/nutrition/gut-microbiome-and-health' target='_blank'>Healthline: Gut Microbiome</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aiche.org/resources/publications/cep/2020/october/developing-precision-microbiome-medicines' target='_blank'>American Institute of Chemical Engineers: Developing Precision Microbiome Medicines</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06036875

Survey to Understand How Black and Hispanic Women Perceive Their Risk for Breast Cancer

CARE: Cancer Risk Perception and Women of Color Scientific Title

Purpose

To study how Black and Hispanic women understand their current and lifetime risk for breast cancer.

Who is this for?

Women, age 25-50 years, who are Black and/or Hispanic and who live in Arizona or Florida with no history of breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey, 1 time</li> <li class="seamTextUnorderedListItem">Interview (optional)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is examining the relationship between risk factors for breast cancer and a person's perceptions of those risk factors and if these relationships are different according to race and ethnicity.</li> <li class="seamTextUnorderedListItem">This study is also exploring how people reduce their risk for breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06036875' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06238986

Studying Gut Health During Chemotherapy in Women with Stage I-III Breast Cancer

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy Scientific Title

Purpose

To study the relationship between changes in gut bacteria and gut symptoms in women with breast cancer receiving chemotherapy.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy or completed chemotherapy within the past 5 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood and stool (poop) samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found on your body.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Certain types of chemotherapy can affect the gut and may affect the bacteria in the gut.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06238986' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 671 miles
Banner - MD Anderson Cancer Center
Gilbert,AZ

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT00477100

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Inflammatory Breast Cancer (IBC) Registry Scientific Title

Purpose

To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.

Who is this for?

People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inflammatory breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen.</li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for inflammatory breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2006-1072.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>NCI: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li></ul>

NEAREST SITE: 804 miles
Bozeman Health Deaconess Hospital
Bozeman,MT

VISITS: One visit every year

PHASE: NA

NCT ID: NCT02012699

iCaRe2: Integrated Cancer Data Repository for Cancer Research

Integrated Cancer Repository for Cancer Research Scientific Title

Purpose

To study cancer risk factors, cancer prevention, early detection and personalized cancer treatments by creating a data registry and biobank.

Who is this for?

People who have or are at risk for developing breast cancer and other cancers. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

This is a data collection (registry) study. You will: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide biospecimens (blood, urine, tissue) for the biobank</li> <li class="seamTextUnorderedListItem">Complete questionnaires, once a year</li> <li class="seamTextUnorderedListItem">Participate in follow-up visits with your healthcare provider, once a year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research sites will implement and maintain a comprehensive data and biospecimen bank known as the Integrated Cancer Repository for Cancer Research (iCaRe2). </li> <li class="seamTextUnorderedListItem">Participants will provide blood, urine and tissue samples for the biobank. </li> <li class="seamTextUnorderedListItem">The data registry and biospecimen bank is made available for research on cancer and other chronic diseases.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02012699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://icare2project.org' target='_blank'>iCaRe2 Project</a> </li></ul>

NEAREST SITE: 941 miles
University of Colorado Denver
Aurora,CO

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT01503190

Registry to Study Immune System Response to Breast Cancer in Women Under Age 50

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction Scientific Title

Purpose

To determine how the immune system responds to different types of tumors or to tumors that develop during or after a pregnancy. Some of the breast cancer tissue collected in this study will be used to create models that develop and test new drug treatments.

Who is this for?

Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are 50 years or younger. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue, blood, and urine samples, if recently diagnosed</li> <li class="seamTextUnorderedListItem">Tissue donation only, if enrolled after treatment has begun or has ended</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are interested in learning more about the role the immune system plays in cancer. </li> <li class="seamTextUnorderedListItem">This study is looking specifically at the level of immune suppression seen in breast cancer that occurs in women under age 50.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01503190' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/tips/immune/' target='_blank'>Breastcancer.org: Understanding Your Immune System</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.youngsurvival.org/' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/faculty/Pages/VirginiaFBorges,MD.aspx' target='_blank'>Lead Researcher: Virginia F. Borges, MD</a> </li></ul>

NEAREST SITE: 1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays,KS

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02302742

A Registry for People with Triple Negative or ER Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT) Scientific Title

Purpose

To learn more about the relationship between genetic mutations and cancer outcomes.

Who is this for?

People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

This is a data collection (registry) study. You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>

NEAREST SITE: 1455 miles
Sanford Health Worthington
Worthington,MN

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05889988

Studying Nerve Pain from T-DM1 in People with Stage I-IV HER2 Positive Breast Cancer

A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Scientific Title

Purpose

To study how trastuzumab emtansine (T-DM1, Kadcyla®) causes nerve pain in people with and without previous nerve pain.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer who are planning to receive treatment with trastuzumab emtansine (T-DM1, Kadcyla®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropathy is nerve pain in your hands and feet as a side effect of cancer treatment. Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®) is an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An ADC is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells. Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">T-DM1's antibody targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called emtansine.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05889988' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/kadcyla' target='_blank'>Breastcancer.org: Trastuzumab Emtansine (T-DM1, Kadcyla®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/neuropathy' target='_blank'>Breastcancer.org: Nerve Pain</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06217874

Registry for People with Metastatic Breast Cancer, Breast Cancer That Has Come Back, or Male Breast Cancer

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer Scientific Title

Purpose

To create a collection of tissue samples and patient information.

Who is this for?

Women with stage I, stage II, or stage III breast cancer that has come back (recurred) or stage IV (metastatic) breast cancer, and men with breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor biopsy sample</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue and blood samples and patient information can be used to improve researchers' understanding of the development, progression, and treatment of breast cancer.</li> <li class="seamTextUnorderedListItem">In this study, information is being collected about metastatic breast cancer, recurrent breast cancer (breast cancer that has come back), and Male Breast Cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06217874' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20309083' target='_blank'>Mayo Clinic: Trial page</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 2 visits

PHASE: NA

NCT ID: NCT04692324

Registry of CSF Biomarkers from Lumbar Punctures for Brain Metastasis

Cerebrospinal Fluid Biomarkers for Brain Tumors Scientific Title

Purpose

To collect samples of CSF to study brain tumor biomarkers and develop new ways to diagnose, monitor, and treat brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF, 2 or more times</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to collect a sample of fluid that surrounds your brain and spinal cord, called cerebrospinal fluid (CSF).</li> <li class="seamTextUnorderedListItem">Biomarkers can indicate the presence or severity of brain tumors.</li> <li class="seamTextUnorderedListItem">You may choose to undergo additional lumbar punctures to collect additional CSF samples.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06285747

Lymphedema, Quality of Life, and Shoulder Function for Women with Stage 0-IV Breast Cancer

A Correlational Study: Breast Cancer-Related Chest Wall Lymphedema, Quality of Life, and Shoulder Function Scientific Title

Purpose

To study how swelling in the chest following breast cancer treatment may affect quality of life and shoulder function.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chest wall and breast lymphedema measurements</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that develops as a side effect of breast cancer treatments like surgery and radiation therapy.</li> <li class="seamTextUnorderedListItem">Lymphedema can affect a person's quality of life and shoulder function and can persist for a long time.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06285747' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05694559

Inherited Cancer Genetic Testing for Black Individuals and Families

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics Scientific Title

Purpose

To connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it.

Who is this for?

Black or African-American individuals over 18 years of age that live near Houston, Texas. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saliva collection kit to collect a saliva sample for genetic testing</li> <li class="seamTextUnorderedListItem">Screening form to assess your risk of hereditary breast cancer</li> <li class="seamTextUnorderedListItem">Counseling about genetic testing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing looks for changes, sometimes called mutations or variants, in your DNA.</li> <li class="seamTextUnorderedListItem">You will also receive counseling about what genetic testing is, why you are eligible, how to receive genetic testing, and that you will be connected to a genetic counselor if you have a pathogenic mutation (PV) of a variant of unknown significance (VUS).</li> <li class="seamTextUnorderedListItem">You will also receive resources for family cascade genetic testing.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05694559' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/risk-factor/gene-mutations-genetic-testing/genetic-counseling-for-people-who-do-not-have-breast-cancer/' target='_blank'>Susan G. Komen: Genetic Testing for People Who Do Not Have Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/disease/cascade_testing/index.htm' target='_blank'>Centers for Disease Control and Prevention: Cascade Testing</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05056857

Studying the Effects of Tamoxifen in People with ER+ Breast Cancer

Neutrophil Functions in Breast Cancer Scientific Title

Purpose

To study the long-term effects of tamoxifen (Nolvadex®) on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects.

Who is this for?

Pre-menopausal and post-menopausal women with stage I, stage II, stage III, or stage IV (metastatic) estrogen receptor positive (ER+) breast cancer receiving treatment with tamoxifen for at least 6 months. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neutrophil extracellular traps (NET) are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system.</li> <li class="seamTextUnorderedListItem">Treatment with tamoxifen (Nolvadex®) increases the production of NETs.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05056857' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/drugs/9785-tamoxifen' target='_blank'>Cleveland Clinic: Tamoxifen (Nolvadex®)</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1-2 visits over 1-2 days

PHASE: NA

NCT ID: NCT04678414

A Fertility Survey of Women with Stage I, Stage II, or Stage III Breast Cancer

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer Scientific Title

Purpose

To study how women decide whether or not to try to have a baby after a breast cancer diagnosis.

Who is this for?

Women who were age 45 or younger when diagnosed with stage I, stage II, or stage III breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One 90-minute focus group</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A 15-30 minute online survey, twice</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One telephone survey</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use the information gathered to help people with cancer make decisions about cancer treatment and family planning.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04678414' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0477.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ccrcal.org/learn-about-ccr/about-cancer-registries/' target='_blank'>California Cancer Registry: About the California Cancer Registry</a> </li></ul>

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06417710

Developing a Nervous System Exam for People With Leptomeningeal Metastasis

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis (NANO-LM) Scientific Title

Purpose

To develop a nervous system (neurological) exam for people with leptomeningeal metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nervous system exam</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The nervous system exam being developed in this study may be used in clinical trials and routine care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06417710' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: Up to 2 visits

PHASE: NA

NCT ID: NCT06127797

Registry of Breast MRI After Treatment for Women with Dense Breasts

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue Scientific Title

Purpose

To study people with dense breast tissue (tissue that is more difficult to see on mammogram) who received a breast MRI scan.

Who is this for?

Women 18-50 years old with stage I, stage II, or stage III breast cancer and dense breast tissue who have completed treatment and are planning to receive a breast MRI scan. You must be receiving care at MD Anderson Cancer Center in Houston, Texas. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, in-person or by phone/email, 2 times before and after breast MRI scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In people with dense breast tissue, breast cancer is difficult to see on a mammogram.</li> <li class="seamTextUnorderedListItem">Breast MRI may improve detection of breast cancer in people with dense breast tissue.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06127797' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every week until end of proton therapy, then 1-4 visits every year

PHASE: NA

NCT ID: NCT00991094

Data Collection to Study Proton Therapy Side Effects

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults Scientific Title

Purpose

To help researchers predict the risk of side effects of proton therapy and understand the long-term benefit of proton therapy.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive proton therapy at University of Texas M. D. Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Review of side effects, weekly during proton therapy, then 1-4 visits every year</li> <li class="seamTextUnorderedListItem">Questionnaires, weekly during proton therapy, then every 2 weeks for 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be monitored for safety and side effects during the visits.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00991094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/radiation-therapy/proton-therapy' target='_blank'>American Society for Clinical Oncology: Proton Therapy</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05649072

Genetic Testing and Counseling for Women in Texas

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. Scientific Title

Purpose

To provide genetic testing and counseling to underserved women at risk for breast cancer.

Who is this for?

Women ages 40 to 74 who live in Texas, do not have health insurance, and are planning to receive a mammogram through the Project VALET program. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing and counseling</li> <li class="seamTextUnorderedListItem">Questionnaire</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will provide a saliva sample for genetic testing when you arrive at your Project VALET mammogram appointment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05649072' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/about-md-anderson/business-legal/office-of-health-policy/project-valet.html#:~:text=Project%20VALET%20(Providing%20Valuable%20Area,are%20patients%20in%20participating%20clinics.' target='_blank'>MD Anderson Cancer Center: Project VALET Mammogram Screening</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing</a> </li></ul>

NEAREST SITE: 1832 miles
Medical College of Wisconsin
Milwaukee,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06383026

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Understanding Breast Cancer Risk and Screening in Transgender and Gender-Diverse Persons Through a Pilot Breast Cancer Screening Program Scientific Title

Purpose

To study the breast cancer screening perceptions and experiences of transgender and gender-diverse people and understand factors that make breast cancer screening more difficult.

Who is this for?

Transgender and gender-diverse people at least 30 years old who have received gender-affirming hormone therapy. You must not have a history of breast cancer or a known genetic mutation that increases your risk for breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram</li> <li class="seamTextUnorderedListItem">Whole breast ultrasound</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transgender and gender-diverse people may experience barriers and non-equitable treatment by healthcare professionals that make receiving breast cancer screening more difficult.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06383026' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1851 miles
Pennington Biomedical Research Center
Baton Rouge,LA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06318507

Studying Gut Bacteria After Immunotherapy in People with Stage I-III Triple Negative Breast Cancer

The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy (IMPACT) Scientific Title

Purpose

To study how bacteria in the gut are different between women with stage I-III triple negative breast cancer who are obese and respond to immunotherapy compared to women who do not respond to immunotherapy.

Who is this for?

Women with newly diagnosed stage I, stage II, or stage III triple negative (ER-, PR-, HER2-) breast cancer who are overweight or obese (BMI 25+) and have not yet received treatment. You must be planning to receive neoadjuvant (before surgery) pembrolizumab (Keytruda®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool (poop) sample</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapy drugs trigger the immune system to see, go after, and kill cancer cells.</li> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found on your body.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Bacteria in the gut may also play a role in whether or not someone responds to immunotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06318507' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: 1 visit every 2-4 weeks for 6 months

PHASE: NA

NCT ID: NCT05674578

Health Coaching and Patient Navigation After Treatment for Black Women

Supporting Black Breast Cancer Survivors: Feasibility Trial of Health Coaching-Based Navigation at the Conclusion of Treatment Scientific Title

Purpose

To study the impact of health coaching with a Black patient navigator on the quality of life of Black women after breast cancer treatment.

Who is this for?

Black women with stage I, stage II, or stage III breast cancer who have completed treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health coaching with a Black patient navigator, every 2-4 weeks for 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health coaching will include physical rehabilitation, emotional and psychosocial support, and nutrition and exercise programming.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05674578' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/survivorship-during-and-after-treatment/be-healthy-after-treatment/nutrition-and-physical-activity-during-and-after-cancer-treatment.html' target='_blank'>American Cancer Society: Nutrition and Physical Activity During and After Cancer Treatment</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05503251

Improving Quality of Life and Cognitive Function After Radiation Therapy for People with Brain Metastases

Effect of Early Integrated Neuropsychological Care in Patients With Brain Metastases - A Phase 2 Randomized Controlled Trial Scientific Title

Purpose

To study if neuropsychological evaluations can improve quality of life or cognitive function after radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. You must not have previously received whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropsychological evaluations, 3 times within 6 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No neuropsychological evaluations</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Quality of life refers to the overall enjoyment of life. It holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.</li> <li class="seamTextUnorderedListItem">Neuropsychological evaluation is used to examine the cognitive consequences of brain damage, brain disease, and severe mental illness.</li> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05503251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: At least 1 visit

PHASE: NA

NCT ID: NCT04022616

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients Scientific Title

Purpose

To study immune cells involved in breast cancer.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have not yet received surgery, or women with stage IV (metastatic) breast cancer. You must be receiving care at the Ohio State Comprehensive Cancer Center or Stefanie Spielman Comprehensive Breast Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor and/or lymph node samples (if removed during surgery)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Natural killer (NK) cells are immune cells that identify and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Myeloid derived suppressor cells (MDSC) are immune cells that kill NK cells, which helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this study, researchers will look for and study these types of immune cells in the blood, tumor, and/or lymph node samples.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04022616' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05946668

Studying Vaginal Microbiome and Vaginal Health in Women with HR+, HER2- Stage I-III Breast Cancer

The VAginal Microbiome as a BiomaRker of VagInal Health in Women With BreaSt CancEr (ARISE) Scientific Title

Purpose

To study how the vaginal microbiome affects vaginal and sexual health.

Who is this for?

Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive or receiving hormone therapy. You must be receiving care at the Ohio State University Medical Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collect vaginal swabs using a self-collection kit</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy may affect sexual health and may cause women to stop having sex.</li> <li class="seamTextUnorderedListItem">The vaginal microbiome is the collection of all microorganisms, such as bacteria, fungi, and viruses, that naturally live inside the vagina. The vaginal microbiome may play a role in menopausal-related sexual health symptoms.</li> <li class="seamTextUnorderedListItem">A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05946668' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://rightasrain.uwmedicine.org/well/health/vaginal-microbiome' target='_blank'>University of Washington: The Vaginal Microbiome</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/vaginal-dryness' target='_blank'>Breastcancer.org: Vaginal Changes with Hormone Therapy</a> </li></ul>

NEAREST SITE: 2299 miles
Levine Cancer Institute
Charlotte,NC

VISITS: 1 visit every month for 4-6 months

PHASE: NA

NCT ID: NCT04174742

Questionnaires to Study Pain During Chemotherapy for Women with Stage I-III Breast Cancer

Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer Scientific Title

Purpose

To study if younger women experience pain during treatment with chemotherapy and pegfilgrastim (Neulasta®) more often and/or at higher levels than older women.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy and pegfilgrastim (Neulasta®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires about pain</li> <li class="seamTextUnorderedListItem">Blood test, monthly for 4-6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pegfilgrastim (Neulasta®) is given to help prevent infections in people who are receiving some types of chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174742' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2299 miles
Levine Cancer Institute
Charlotte,NC

VISITS: At least 3 visits within 1 month

PHASE: NA

NCT ID: NCT06291324

Studying the Relationship Between Heart Rate Variability and Fatigue During Treatment for Stage I-IV Breast Cancer

Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment Scientific Title

Purpose

To study the relationship between heart rate variability (HRV) and fatigue during cancer treatment.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive or are receiving treatment. You must be experiencing fatigue (tiredness). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear activity tracker device, 1 month</li> <li class="seamTextUnorderedListItem">Diary of activity tracker information, 1 month</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The activity tracker device measures your heart rate variability (HRV).</li> <li class="seamTextUnorderedListItem">Heart rate variability (HRV) is the fluctuations in the amount of time between your heartbeats.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06291324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/symptoms/21773-heart-rate-variability-hrv' target='_blank'>Cleveland Clinic: Heart Rate Variability</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04526587

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Scientific Title

Purpose

To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>

NEAREST SITE: 2314 miles
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03987555

Studying the Amount of Chemotherapy in the Blood in People with Breast Cancer

Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Scientific Title

Purpose

To study the ability of researchers to measure the amount of paclitaxel (Taxol®) in blood and study the effect of paclitaxel (Taxol®) on neuropathy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive treatment with paclitaxel (Taxol®) at Wake Forest Comprehensive Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Surveys about neuropathy</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Nerve damage is one of the most common and severe side effects of paclitaxel (Taxol®).</li> <li class="seamTextUnorderedListItem">The ability to consistently measure paclitaxel (Taxol®) in the blood may allow doctors to control the dose of paclitaxel, so that enough chemotherapy is given to kill the cancer, but the side effect of nerve damage is reduced.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03987555' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>

NEAREST SITE: 2314 miles
Wake Forest Baptist Health Sciences
Winston-Salem,NC

VISITS: 3 visits in 3 months

PHASE: NA

NCT ID: NCT05030038

Impact of Aromatase Inhibitors on Gut Bacteria in People with Stage 0-IV Breast Cancer

Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability Scientific Title

Purpose

To study the bacteria in your gut before and during treatment with an aromatase inhibitor.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving an aromatase inhibitor, or women without breast cancer who are receiving an aromatase inhibitor to reduce their risk of breast cancer. You must not have received antibiotics within the last month. If you have HER2 positive (HER2+) breast cancer, you must not have received an antibody drug conjugate (ADC). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 3 times within 3 months</li> <li class="seamTextUnorderedListItem">Stool samples, 3 times within 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found in your digestive tract. Most of the microbiome consists of bacteria in your digestive system.</li> <li class="seamTextUnorderedListItem">These bacteria can be beneficial or harmful. The harmful bacteria cause disease, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">You will collect fecal samples at home and either mail in the sample or drop it off at the lab.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05030038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hsph.harvard.edu/nutritionsource/microbiome/' target='_blank'>Harvard University: What is the Microbiome?</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/about-us/news-personal-stories/can-gut-bacteria-help-treat-breast-cancer' target='_blank'>Breast Cancer Now: Gut Bacteria and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li></ul>

NEAREST SITE: 2354 miles
University of Florida
Gainesville,FL

VISITS: Coincides with routine care and surgery

PHASE: NA

NCT ID: NCT00811148

University of Florida Brain Tumor Tissue Bank

Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research Scientific Title

Purpose

To collect and store brain tumor tissue samples for brain tumor research.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and are planning to receive brain surgery at the Florida Center for Brain Tumor Research. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research. </li> <li class="seamTextUnorderedListItem">The mission of the Florida Center for Brain Tumor Research is to discover cures and treatments for brain tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00811148' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06349642

Registry to Predict Response to Immune Checkpoint Inhibitors for People with Stage I-IV Breast Cancer

Observational Basket Study to Predict Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform (CYBRID-04) Scientific Title

Purpose

To create a registry to predict response to treatment with immune checkpoint inhibitors.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer or breast cancer with TMB, MSI-H, or dMMR mutations who are planning to receive pembrolizumab (Keytruda®) or dostarlimab (Jemperli®). If you have stage I, stage II, or stage III breast cancer, you must have not yet received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy sample</li> <li class="seamTextUnorderedListItem">Blood sample</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapy may help the body's immune system attack cancer and may reduce the ability of tumor cells to grow and spread.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) and dostarlimab (Jemperli®) are types of immunotherapy called PD-1 inhibitors, which are a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">MSI-H and dMMR mutations include MLH1, MSH2, MSH6, and PMS2.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: TMB, MSI-H, dMMR, MLH1, MSH2, MSH6, PMS2</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06349642' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: At least 1 visit within 10 years

PHASE: NA

NCT ID: NCT05755269

Genetic Risk of Breast Cancer for African American and Hispanic Women

Genetic Risk Estimation in Breast Cancer and Assessing Health Disparities Scientific Title

Purpose

To study whether adding a genetic risk assessment to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about breast cancer screening and prevention.

Who is this for?

African American/Black or Hispanic/Latinx women 30-75 years old with lobular carcinoma in situ (LCIS) or women at risk of breast cancer, including with a history of abnormal biopsy results. You must not have taken drugs to prevent breast cancer for longer than 6 months, received a mastectomy to reduce your risk of breast cancer, or have a breast cancer mutation such as BRCA1/2, PALB2, ATM, or CHEK2. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample for genetic/genomic testing</li> <li class="seamTextUnorderedListItem">Surveys, 2 times in 6 months, then every year for 10 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive your genetic testing results and your risk of breast cancer.</li> <li class="seamTextUnorderedListItem">Traditional breast cancer risk assessments include family history, reproductive history, and breast density.</li> <li class="seamTextUnorderedListItem">This information can be combined with genetic information to provide a 10 year and lifetime risk for breast cancer.</li> <li class="seamTextUnorderedListItem">Including genetics with traditional screening techniques may help minority women make more informed decisions about screening and prevention strategies for breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05755269' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/about-breast-cancer#section-breast-cancer-risk' target='_blank'>Breastcancer.org: Breast Cancer Risk</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: Coincides with surgery and routine care

PHASE: NA

NCT ID: NCT06117930

Registry to Study the Impact of the Gut Microbiome on Brain Tumors

Study of Human Brain-Gut Axis and Gut Microbiome In Patients With Brain Lesions - Repository for Neuroscience Research Scientific Title

Purpose

To study the impact of the gut microbiome on the growth and progression of brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, saliva, urine and stool samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool samples will be used to study your gut microbiome, which are the microorganisms that live in your digestive system.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06117930' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05507879

Registry to Study Heart Problems from Chemotherapy in People with Stage I-III Breast Cancer

Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study) Scientific Title

Purpose

To study the TRPC6 biomarker to predict and prevent chemotherapy-related cardiac toxicity.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are receiving or are planning to receive chemotherapy or trastuzumab (Herceptin®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Understanding how the TRPC6 biomarker is involved in these changes may allow early intervention against cardiac toxicity and also identify new biomarkers to protect long-term cardiac health.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05507879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/16858-chemotherapy--the-heart-cardiotoxicity#:~:text=Cardiotoxicity%20is%20a%20term%20for,radiation%20therapy%20to%20the%20chest.' target='_blank'>Cleveland Clinic: Cardiotoxicity and Cancer Treatment</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: At least 3 visits

PHASE: NA

NCT ID: NCT04517838

Registry to Study Immune Response to Anti-HER2 Targeted Therapy for Stage I-IV HER2+ Breast Cancer

Immune Response to Anti-HER2 Therapies Scientific Title

Purpose

To study the relationship between immune cell response and treatment with anti-HER2 targeted therapy.

Who is this for?

Women with stage I, stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer who are planning to begin treatment with anti-HER2 targeted therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 3 times within 4 months, 1 time at disease recurrence or progression</li> <li class="seamTextUnorderedListItem">Tumor samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor samples will be used for genetic testing.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04517838' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li></ul>

NEAREST SITE: 2385 miles
Duke Cancer Center
Durham,NC

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05480644

Studying Biomarkers, Immune Cells, and ctDNA in People with Brain Metastasis

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors Scientific Title

Purpose

To study biomarkers, immune cells, and circulating tumor (ctDNA) in blood samples after radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive or receiving radiation at Duke Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests will be used for genetic testing to indicate the presence of biomarkers, immune cells, and circulating tumor (ctDNA).</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05480644' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2406 miles
University of North Carolina
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05926024

Factors Impacting Quality of Life of Women After Breast Cancer Treatment

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment Scientific Title

Purpose

To study factors that impact quality of life after breast cancer treatment.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who completed treatment at least 3 years ago and have not had their cancer come back. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The questionnaires will ask about lifestyle factors, physical health, social life/family, emotional/mental health, fatigue, ability to think, pain, anxiety, depression, stress, sexual function, and treatment side effects.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05926024' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/survivorship/health-concerns/quality-of-life/#:~:text=Quality%20of%20life%20after%20treatment,even%20years%20after%20treatment%20ends.' target='_blank'>Susan G Komen: Quality of Life After Breast Cancer Treatment</a> </li></ul>

NEAREST SITE: 2453 miles
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore,MD

VISITS: Please contact research site

PHASE: NA

NCT ID: NCT01937039

Johns Hopkins Breast Cancer Program Tissue Bank

Johns Hopkins Breast Cancer Program Longitudinal Repository Scientific Title

Purpose

To study what causes breast cancer and how to treat breast cancer.

Who is this for?

People being seen at Johns Hopkins for breast cancer treatment, or for any screening or diagnostic breast procedures. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide blood, urine, and tissue samples periodically over time (up to 20 years).
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Breast Cancer Program at Johns Hopkins, in Baltimore, Maryland, has started a Longitudinal Repository-also known as a tissue bank.</li> <li class="seamTextUnorderedListItem">The Repository will store blood, breast tissue and urine samples donated periodically for up to 20 years by people with breast cancer or benign breast disease; as well as people never diagnosed with breast cancer. </li> <li class="seamTextUnorderedListItem">The Repository will provide blood, tissue, and urine samples to breast cancer researchers.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01937039' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2517 miles
Abramson Cancer Center
Philadelphia,PA

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT05396612

Studying Immune Cell Response to Treatment for Women with Stage I-III ER+, HER2- Breast Cancer

Role of the Immune Environment in Response to Therapy in Breast Cancer Scientific Title

Purpose

To study differences in immune cells in different types of breast cancer.

Who is this for?

Women with stage I, stage II, or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who are planning to receive surgery at the University of Pennsylvania Health System. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples from surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immune system cells play an important role in finding and killing cancer cells.</li> <li class="seamTextUnorderedListItem">This study will compare immune system cells and their role in outcomes after treatment in different types of breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05396612' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2521 miles
Cooper University Hospital
Camden,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT02749474

Registry to Study Breast Cancer, Pregnancy, and Mother/Child Health

Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being(CANCRPREGREG) Scientific Title

Purpose

To study the treatment options offered to pregnant women diagnosed with cancer and study the impact that their treatment or delay of treatment has on their own health and that of their children.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer diagnosed within 1.5 months of their last menstrual period or up to 6 months after the end of their pregnancy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Permission to access health records</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02749474' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2521 miles
Fox Chase Cancer Center
Philadelphia,PA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05754658

Studying Genetic and Molecular Biomarkers of Breast Cancer in Black Women or Men

African Cancer Genome Cohort to Promote Health Equity Among Patients of African Ancestry: Characterization of Genetic and Molecular Drivers Scientific Title

Purpose

To study genetic and molecular biomarkers of breast cancer in individuals of African ancestry.

Who is this for?

Black women or men with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood and tumor tissues</li> <li class="seamTextUnorderedListItem">Receive genetic testing</li> <li class="seamTextUnorderedListItem">Complete social determinants of health (SDOH) survey</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will also identify the effects of social determinants of health (SDOH) and lifestyle factors on breast cancer mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05754658' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/about/priorities/why-is-addressing-sdoh-important.html#:~:text=Social%20determinants%20of%20health%20(SDOH)%20are%20the%20nonmedical%20factors%20that,live%2C%20worship%2C%20and%20age.' target='_blank'>Centers for Disease Control and Prevention: Social Determinants of Health (SDOH)</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06334354

Changes in Thinking and Memory Over Time for Women with Stage I-III Breast Cancer After Treatment

Cognitive Aging in Older Long-term Breast Cancer Survivors (TRAC) Scientific Title

Purpose

To study how differences in mental function develop over time in breast cancer survivors compared to people without a history of cancer.

Who is this for?

Women 65-80 years old with stage I, stage II, or stage III breast cancer who were diagnosed between 55-60 years old and have completed treatment, and people who do not have a history of breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online surveys</li> <li class="seamTextUnorderedListItem">Saliva (spit) sample, by mail</li> <li class="seamTextUnorderedListItem">Urine sample</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Problems with thinking such as problems with memory, attention, and information processing may occur in people who were previously treated for breast cancer compared to those without a history of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06334354' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge
Basking Ridge,NJ

VISITS: 4 visits over 1 year, then annual visits for 5 years

PHASE: NA

NCT ID: NCT01788839

Sexual and Reproductive Health of Women Treated for Breast Cancer

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma Scientific Title

Purpose

To study how to identify which women are most likely to develop early menopause or sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment.

Who is this for?

Women, 50 or younger, diagnosed with DCIS or stage I, stage II, or stage III breast cancer who are within one month of starting treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sexual and Reproductive Health survey, 9 times over 5 years</li> <li class="seamTextUnorderedListItem">If you receive chemotherapy, optional blood draw, 3 times over 2 years</li> <li class="seamTextUnorderedListItem">If you are premenopausal and only receive tamoxifen, blood draws, 12 times over 2 years and transvaginal ultrasound, 2 times, at baseline and 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer and its treatment may affect sexual and reproductive health.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling women with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01788839' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.mskcc.org/cancer-care/trial/12-249' target='_blank'>Memorial Sloan Kettering Cancer Center: Study Website</a> </li></ul>

NEAREST SITE: 2569 miles
Brooklyn Methodist Hospital - NewYork Presbyterian
New York,NY

VISITS: Coincides with routine care and surgery

PHASE: NA

NCT ID: NCT05134779

Tumor Registry for Triple Negative Breast Cancer

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You Scientific Title

Purpose

To create a large registry of tumor samples, called a biobank or tumor bank, to help researchers study triple negative breast cancer and discover new treatments.

Who is this for?

People with stage I, stage II, stage III, or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following at different timepoints during your treatment: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and tumor samples will be taken at the following timepoints (if relevant): diagnosis, surgery, recurrence, and/or metastasis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05134779' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/triple-negative' target='_blank'>Breastcancer.org: Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://seer.cancer.gov/registries/cancer_registry/index.html' target='_blank'>National Cancer Institute: What is a Cancer Registry?</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org/' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>

NEAREST SITE: 2570 miles
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04751435

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients Scientific Title

Purpose

To develop educational materials about genetic testing for people that speak different languages and have diverse cultural backgrounds.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing is a type of test that detects changes to the genes, the DNA instructions that are passed on from the mother and father.</li> <li class="seamTextUnorderedListItem">The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder.</li> <li class="seamTextUnorderedListItem">The information gathered from your interview will be used to develop educational materials about genetic testing.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04751435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease Control and Prevention: Genetic Testing</a> </li></ul>

NEAREST SITE: 2573 miles
Cleveland Clinic Florida
Weston,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05598879

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Global Cardio Oncology Registry Scientific Title

Purpose

To collect information on the diagnosis and treatment of cardiovascular health and risk factors in people with breast cancer.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of health information</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">This study uses clinical, laboratory, imaging, demographic, and socioeconomic information to study cardiovascular (heart and blood vessels) health and risk factors before, during, or after cancer treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05598879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.heart.org/en/news/2020/02/19/what-women-need-to-know-about-breast-cancer-and-heart-disease' target='_blank'>American Heart Association: Breast Cancer and Heart Disease</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04379414

YES Portal for Monitoring Symptoms and Providing Support for Women Ages 18-39 with Breast Cancer

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Newly Diagnosed/Metastatic Intervention Scientific Title

Purpose

To study the ability of the web-based YES portal to monitor cancer symptoms and provide support and educational resources.

Who is this for?

Women newly diagnosed with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer between the ages of 18-39 years who are planning to receive treatment at Dana-Farber Cancer Institute. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to YES portal, weekly for 3 months, then monthly</li> <li class="seamTextUnorderedListItem">Surveys, every 6 months for 3 years, then yearly for 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Young, Empowered, and Strong (YES) portal is a web-based portal designed to help monitor cancer-related issues and to share self-management information, resources, and potential research opportunities.</li> <li class="seamTextUnorderedListItem">The portal is also designed to create a community among participants through the yeschat.org discussion board.</li> <li class="seamTextUnorderedListItem">The portal can be accessed by smartphone, tablet, or laptop/desktop.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04379414' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials2/detail/20-124/' target='_blank'>Dana-Farber Cancer Institute Trial Information Page: YES Portal</a> </li><li class='seamTextUnorderedListItem'><a href='https://youngandstrong.dana-farber.org/' target='_blank'>Dana-Farber Cancer Institute: Young and Strong</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/CCI.21.00067' target='_blank'>Abstract: YES Portal</a> </li></ul>

No Travel Required

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04379570

Telephone and Online Support for Women with Stage I-III, HR+, HER2- Breast Cancer Taking Anti-Estrogen Therapy

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions Scientific Title

Purpose

To study if different types of telephone and online education can help women take their anti-estrogen therapy.

Who is this for?

Women with stage I, stage II or stage III hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have started taking anti-estrogen therapy within the last 6 months or intend to start taking it within the next 6 weeks. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 4 groups and receive the following: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online education about anti-estrogen therapy, 1 time</li> <li class="seamTextUnorderedListItem">Text message reminders to take anti-estrogen therapy, daily, for 9 months</li> <li class="seamTextUnorderedListItem">Test messages asking about side effects and taking anti-estrogen therapy, monthly, for 9 months</li> <li class="seamTextUnorderedListItem">Questionnaires </li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online education about anti-estrogen therapy, 1 time</li> <li class="seamTextUnorderedListItem">Motivational telephone therapy sessions, 5 times, over 9 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online education about anti-estrogen therapy, 1 time</li> <li class="seamTextUnorderedListItem">Text message reminders to take anti-estrogen therapy, daily, for 9 months</li> <li class="seamTextUnorderedListItem">Test messages asking about side effects and taking anti-estrogen therapy, monthly, for 9 months</li> <li class="seamTextUnorderedListItem">Motivational telephone therapy sessions, 5 times, over 9 months</li> <li class="seamTextUnorderedListItem">Questionnaires </li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online education about anti-estrogen therapy, 1 time</li> <li class="seamTextUnorderedListItem">Optional online education about healthy living</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying whether text messaging, online education, and telephone support can help women take their anti-estrogen therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04379570' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/expect' target='_blank'>Breastcancer.org: Hormonal Therapy, What to Expect</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT06387173

Registry of Cryoablation for Stage I-III Breast Cancer

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer Scientific Title

Purpose

To study the side effects and outcomes of people who receive cryoablation for breast cancer.

Who is this for?

People with stage I, stage II, or some stage III breast cancer who are planning to receive cryoablation to freeze and destroy cancer cells. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Permission to access medical records</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation is a procedure in which an extremely cold liquid or device is used to freeze and destroy cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06387173' target='_blank'>ClinicalTrials.gov</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04967352

Predicting Pain After Surgery for Stage I-III Breast Cancer

Development of Predictive Models Using Artificial Intelligence for Postoperative Chronic Pain and Opioid Use Following Breast Surgery: A Prospectively-Designed Study Scientific Title

Purpose

To collect data to predict who will experience chronic pain after breast surgery.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Mouth swab</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast surgery may lead to chronic (long term) pain in many people.</li> <li class="seamTextUnorderedListItem">Personalized pain management may control pain with the least amount of medications.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04967352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/side-effects/managing-pain/' target='_blank'>Susan G Komen: Pain From Breast Surgery</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04028479

Registry to Improve Diagnosis and Treatment of Breast Cancer

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Scientific Title

Purpose

To create a registry of diagnosis, testing, biomarker, treatment, and patient-reported outcomes data to improve cancer diagnosis and treatment.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Consent for data collection</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04028479' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://taprootco.com/root/' target='_blank'>Taproot Health: Trial Information Page</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05715255

Counseling by Phone to Help Manage Side Effects of Immunotherapy for Stage II-IV Breast Cancer

Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors Scientific Title

Purpose

To study whether telephone-based counseling will improve your ability to manage immunotherapy side effects.

Who is this for?

People with stage II, stage III, or stage IV (metastatic) breast cancer who have begun treatment with an immune checkpoint inhibitor within the past 3 months. You must be experiencing at least mild psychological distress. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Counseling, by phone call, weekly</li> <li class="seamTextUnorderedListItem">Handbook about managing side effects</li> <li class="seamTextUnorderedListItem">Assessment of side effects, weekly</li> <li class="seamTextUnorderedListItem">Interviews, 2 times within 4 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Assessment of side effects, weekly</li> <li class="seamTextUnorderedListItem">Interviews, 2 times within 4 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapies are drugs that trigger the immune system to see, go after, and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Side effects from immunotherapy are common.</li> <li class="seamTextUnorderedListItem">The ability to manage the side effects you experience from immunotherapy may reduce your distress, prevent treatment interruption, and lead to fewer visits to your doctor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05715255' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/treatment/immunotherapy.html#:~:text=Possible%20side%20effects%20of%20immune,reaction%20while%20getting%20these%20drugs.' target='_blank'>American Cancer Society: Immune Checkpoint Inhibitors for Breast Cancer and Their Side Effects</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05838417

Survey to Understand Breast Cancer Screening Knowledge and Attitudes

Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study Scientific Title

Purpose

To study attitudes and knowledge about breast cancer screening and to determine if conversations with primary care doctors increase breast cancer screening.

Who is this for?

Women 39-49 years old who have not been diagnosed with breast cancer and do not have a known BCRA1/2 gene mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys, by email or phone, 4 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conversations between primary care doctors and healthy women may affect women's attitudes and understanding of breast cancer screening and therefore may increase screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05838417' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammograms/recommendations' target='_blank'>Breastcancer.org: Mammogram Screening Guidelines</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05612100

Studying Alopecia During Hormone Therapy in Women with Breast Cancer

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors Scientific Title

Purpose

To study the incidence, timing, duration, and severity of alopecia (hair loss) during hormone therapy.

Who is this for?

Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">While alopecia (hair loss) is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing hormone therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05612100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Alopecia/Hair Loss</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05654246

Susan G. Komen ShareForCures Research Registry

ShareForCures: Susan G. Komen's People-powered, Data-driven Breast Cancer Research Registry Scientific Title

Purpose

To create a research registry of data from people with breast cancer, including minority and marginalized people, to ensure data is as diverse as the people touched by the disease.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Saliva samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will have a better understanding of breast cancer and everyone can potentially benefit from scientific advances and improvements in care.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05654246' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/shareforcures/' target='_blank'>Susan G. Komen: ShareForCures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/npcr/value/registries.htm' target='_blank'>Centers for Disease Control and Prevention: How Cancer Registries Work</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04169542

Questionnaires to Understand Financial Impacts of Surgery and COVID-19 for Women Receiving a Mastectomy

Financial Toxicity in Patients Undergoing Breast Reconstruction: The Impact of Out of Pocket Costs, Lost Wages and Unemployment Scientific Title

Purpose

To collect information about the financial impact of breast cancer surgery and to learn if the COVID-19 pandemic affects patient costs of breast reconstruction.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer or women at high risk for breast cancer who are planning to receive a mastectomy and breast reconstruction at MD Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 4 times within 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving breast reconstruction after a mastectomy are at high risk for financial toxicity (harmful effects of high health care cost on well-being).</li> <li class="seamTextUnorderedListItem">The COVID-19 pandemic may affect these costs.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04169542' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/resources-support/find-financial-support-cancer/' target='_blank'>Metastatic Trial Talk: Where to Find Financial Support</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05483283

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care Scientific Title

Purpose

To compare the impact of empowerment and navigation sessions with standard of care sessions on whether Latina women decide to receive genetic testing and/or genetic counseling.

Who is this for?

Latina women ages 30+ with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or with a family history of breast or ovarian cancer. You must have one social determinant of health risk factor, such as: perceived financial struggles, transportation difficulties, exposure to violence, housing challenges, social isolation/challenges. You must not have received genetic testing or genetic counseling. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, breast cancer screening, and diet and physical activity for breast cancer prevention.</li> <li class="seamTextUnorderedListItem">Standard of care sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, how to share breast cancer information, and testimonials and include role playing activities and group discussions.</li> <li class="seamTextUnorderedListItem">You can receive up to $100 for participation.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05483283' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/making-the-case-for-health-equity.pdf' target='_blank'>American Cancer Society: Health Equity and Social Determinants of Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.gov/healthypeople/priority-areas/social-determinants-health' target='_blank'>US Department of Health and Human Services: Social Determinants of Health</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05981716

Quality of Life Survey for Young Women After Breast Cancer Treatment

Factors Affecting Quality of Life and Treatment Adherence Among Early-Age-at-Onset Breast Cancer Survivors Scientific Title

Purpose

To study the quality of life of women after completing breast cancer treatment.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have completed treatment. You must have been diagnosed within the past 10 years and diagnosed before age 50. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete online survey</li> <li class="seamTextUnorderedListItem">You will be entered to win a $50 electronic gift card in appreciation for your time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you are interested in participating, reach out to Dr. Susan Steck at stecks@mailbox.sc.edu or 803-777-1527.</li> <li class="seamTextUnorderedListItem">The survey will ask about factors that impact your quality of life, such as your diet and social determinants of health (SDOH).</li> <li class="seamTextUnorderedListItem">Social determinants of health (SDOH) describe non-medical factors that influence your health, such as race, gender, education, work, and access to resources.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05981716' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ybcss2.org/' target='_blank'>Trial Information Page: Young Breast Cancer Survivor Study (YBCSS)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/survivorship/health-concerns/quality-of-life/' target='_blank'>Susan G. Komen: Quality of Life After Breast Cancer Treatment</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT06096623

Questionnaires to Prevent Treatment Delays for People with Newly Diagnosed Stage I-IV Breast Cancer

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparities in Cancer Treatment Delay Scientific Title

Purpose

To understand when patients may be at risk of treatment delays and to help patients get treatment faster.

Who is this for?

People with newly diagnosed stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have been diagnosed within the past 1.5 months and are planning to receive treatment at the University of North Carolina. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patient reported outcome (PRO) questionnaires, weekly for 2 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A patient reported outcome (PRO) is information reported during a clinical trial by a person with breast cancer without interpretation by a doctor or anyone else.</li> <li class="seamTextUnorderedListItem">The questionnaires will identify social determinants of health (SDOH), the non-medical factors that influence your health, such as race, gender identity, education, occupation, access to health services and economic resources.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06096623' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/blog/2023-06/what-are-patient-reported-outcomes-and-why-are-they-important-cancer-care' target='_blank'>Cancer.Net: What Are Patient-Reported Outcomes and Why Are They Important in Cancer Care?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/about/sdoh/index.html' target='_blank'>Centers for Disease Control and Prevention: Social Determinants of Health (SDOH)</a> </li></ul>

No Travel Required

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02333604

CSC Online Survey: The Cancer Experience Registry

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER) Scientific Title

Purpose

To learn more about the emotional and social experiences and needs of people affected by cancer.

Who is this for?

People diagnosed with DCIS, stage I, stage II, stage III, or metastatic (stage IV) breast cancer and people who provide care to individuals diagnosed with cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Participation in this study involves the completion of an online questionnaire. The questionnaire may be accessed at the following link: <a href="http://www.cancersupportcommunity.org/MainMenu/ResearchTraining/Cancer-Experience-Registry.html" target="_blank">www.cancerexperienceregistry.org</a>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use this information to improve the educational materials and the overall quality of care that cancer patients receive. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer. </li> <li class="seamTextUnorderedListItem">The data collected from this study can be found <a href="https://www.cancersupportcommunity.org/RegistryIndexReport2017" target="_blank">here.</a></li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02333604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerexperienceregistry.org/' target='_blank'>Cancer Support Community Study Website: Cancer Experience Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancersupportcommunity.org/RegistryIndexReport2017' target='_blank'>Cancer Support Community: Cancer Experience Registry Index Report 2017</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youtube.com/watch?v=SyyUYqyNaCc' target='_blank'>Cancer Support Community YouTube Channel: What is the Cancer Experience Registry?</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT06604078

Registry to Use Artificial Intelligence to Improve Breast Cancer Screening

Elucidating the Impact of Social Wellness and Artificial Intelligence on the Psychological Consequences of Breast Cancer Imaging Scientific Title

Purpose

To use artificial intelligence (AI) to detect breast cancer earlier and more accurately.

Who is this for?

Anyone who has received a mammogram. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be asked to: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Upload mammogram images</li> <li class="seamTextUnorderedListItem">Use social platform (optional)</li> <li class="seamTextUnorderedListItem">Complete questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer screening can cause stress and anxiety from false positive or unknown results.</li> <li class="seamTextUnorderedListItem">This UCF WEALTH platform is one of the first projects that allows patients to donate their breast cancer mammogram imaging results to reduce the mental challenges using social platforms and artificial intelligence.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06604078' target='_blank'>ClinicalTrials.gov</a> </li></ul>

No Travel Required

VISITS: Mobile or online surveys

PHASE: NA

NCT ID: NCT00000003

MBC Connect Patient Registry: Sharing MBC History, Experiences, and Quality of Life

MBC Connect -- Patient Powered. Research Driven Scientific Title

Purpose

To collect information about the experiences of people with metastatic breast cancer for researchers and clinicians and to provide personalized information to each participant.

Who is this for?

People with metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be asked to fill out surveys about your breast cancer diagnosis, treatment history and quality of life.</li> <li class="seamTextUnorderedListItem">Based on information you enter, you will get personalized insights and alerts with MBC news, events, and clinical trial opportunities.</li> </ul> To join the registry, click here: <a href="https://www.mbcconnect.org/" target="_blank">www.mbcconnect.org/</a>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBC Connect is a free, web and mobile-friendly registry that collects information about the experiences of people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Joining the registry allows you to receive personalized information about MBC-related news, events, and clinical trial opportunities. </li> <li class="seamTextUnorderedListItem">Researchers and clinicians will be able to analyze information collected in the registry in research studies. </li> <li class="seamTextUnorderedListItem">MBC Connect is available in English and Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcconnect.org/' target='_blank'>MBC Connect</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/' target='_blank'>Metastatic Breast Cancer Alliance</a> </li></ul>

No Travel Required

VISITS: Online forms, questionnaires, saliva sample by mail

PHASE: NA

NCT ID: NCT00000002

MBC Project: Collecting Information About Metastatic Breast Cancer To Further Research

The Metastatic Breast Cancer Project Scientific Title

Purpose

To accelerate research in treating, curing and preventing metastatic breast cancer.

Who is this for?

People with metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Your participation will include the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete a simple online form about yourself and your cancer</li> <li class="seamTextUnorderedListItem">Fill out an online consent form that gives your permission for the researchers to obtain copies of your medical records and some of your stored tumor tissue</li> <li class="seamTextUnorderedListItem">Provide a saliva sample and send back via U.S. mail </li> </ul> To learn more and/or to participate, click here: <a href="https://www.mbcproject.org/" target="_blank">https://www.mbcproject.org/</a>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of the Metastatic Breast Cancer Project is to accelerate research in treating, curing and preventing metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you take part in the project, you will fill out questionnaires, provide a saliva sample, and share a piece of your stored tumor tissue and copies of your medical records with the researchers. </li> <li class="seamTextUnorderedListItem">The researchers believe analyzing this data will help them learn more about metastatic breast cancer and make more research advances. </li> <li class="seamTextUnorderedListItem">The MBC Project was created by a coalition of researchers and breast cancer advocacy organizations.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcproject.org/' target='_blank'>The Metastatic Breast Cancer Project</a> </li></ul>